AstraZeneca R&D: Aim Early To Cut Cycle Time, Build Phase II Pipeline
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Current R&D strategy emphasizes improvements to R&D processes, like trying to reduce costs and cycle time. Making go/no-go decisions earlier on is also a goal, R&D execs say in an interview. The firm is in a building phase as it makes up for some major Phase III failures in recent years. AstraZeneca's current late-stage pipeline is mostly focused on lifecycle management